Anlon Healthcare IPO Day 3 Review: GMP, Subscription Status & Investment Outlook Explained
Indian stock market investors have a new opportunity as Anlon Healthcare IPO enters its final bidding day. The demand for active pharmaceutical ingredients (APIs) is growing rapidly in the healthcare and pharmaceutical sector, and amidst this, this IPO has shown its strong entry in the market. But the question is whether this IPO will be a good bet for investors or will it be right to stay away from it? Let’s understand in detail Anlon Healthcare IPO review, GMP update and subscription status.
Anlon Healthcare IPO Day 3: What is the latest subscription status?
Anlon Healthcare IPO was launched in the Indian primary market on Tuesday and it will remain open till 29 August 2025. Meaning now investors have only one day left to apply. By the end of Day 2, the IPO had given a very strong response. According to the data, the IPO was 3.30 times oversubscribed. The highest participation was from retail investors, who subscribed their reserved portion 22.32 times. Non-Institutional Investors (NII) placed bids 2.09 times, while Qualified Institutional Buyers (QIBs) also booked their portion 1.01 times.
These subscription numbers clearly show that Anlon Healthcare IPO is grabbing a lot of attention among investors.
Anlon Healthcare IPO GMP Today
According to market observers, Anlon Healthcare IPO GMP is trading at ₹6 per share today. This GMP is stable at Thursday’s level, which is considered a positive sign as the secondary market is still witnessing a heavy sell-off. The grey market premium remaining stable shows that the sentiments for the IPO are strong.
Apart from this, according to data from Investorgain and IPO Watch, unlisted shares are trading around ₹96 per share, which shows a premium of about 5-7% over the issue price.
Anlon Healthcare IPO Review: Expert Opinions
Investment experts have given mixed reviews on this IPO
Sachin Jasuja, Head of Equities, Centricity WealthTech, says, “The API production sector is being supported by ‘Make in India’ and Production Linked Incentive (PLI) schemes. This policy support is providing subsidies, capex and regulatory ease to local manufacturers, which is very positive for long-term growth.”
On the other hand, Shivani Nyati, Head of Wealth, Swastika Investmart, has a cautious view. She says the company makes specialized APIs and markets its products as per global standards. But, it has a major dependency on a single manufacturing facility (Rajkot, Gujarat). Its revenue growth in FY24 was impacted due to Brazil registration delays. According to Shivani, the valuations of the IPO seem to be fully priced, so one should remain cautious.
Anand Rathi’s report says that Anlon Healthcare IPO is worth investing in for the long term. The P/E ratio of the IPO is 19x and EV/EBITDA is 16.7x which is good as per the market average.
Harshal Dasani of INVasset PMS says that “The company operates on a modest scale and does not have a dividend history yet. But due to custom synthesis and planned expansion, its long-term potential can be strong. This IPO is right for those investors who want to take risk and understand the sector well.”
Anlon Healthcare IPO Details
Rajkot-based company Anlon Healthcare has set a target of raising ₹121 crore through its IPO. The company has priced at ₹86-91 per share and will issue 1.33 crore fresh equity shares.
The minimum bid is for 164 shares, which at the upper price band works out to an investment of ₹14,924. The IPO allotment date is expected to be 30 August 2025 (or 1 September 2025 if there is further delay), and the listing date is likely to be 3 September 2025 on BSE and NSE.
The money raised through the IPO will be mainly used for the company’s manufacturing facility expansion (₹30.7 crore), working capital (₹43.15 crore), debt repayment and general corporate purposes.
Should You Apply for Anlon Healthcare IPO?
This is the most important question for investors. If you are a retail investor looking to park capital for the long-term, then Anlon Healthcare IPO can be a good option as the sector is getting strong policy and demand support. But the situation looks a bit tricky for short-term listing gains as valuations are fully priced for now.
If you are risk-averse, it is better to take a wait and watch approach. But if you like the long-term growth story of healthcare and pharma API segment, then this IPO can be a strategic bet.
Final Verdict on Anlon Healthcare IPO
The future of healthcare and pharma API sector looks strong and Anlon Healthcare IPO has won the trust of retail investors. Grey market premium is also stable which supports the sentiment. But high valuations and single facility dependency cannot be ignored.
Listing gains seem limited in the short-term, but for long-term investors this IPO can be a calculated risk.
Disclaimer:
This article is for informational purposes only. The views expressed in it are based on market experts and publicly available data. This is not an investment advice of any kind. Consult your financial advisor before taking any investment decision.
Also Read
Upcoming IPOs 2025: Vikran Engineering, Anlon Healthcare & Other Hot Public Issues Next Week
